Ahrens FA and Aronson AL. A comparative study of the toxic effects of calcium and chromium chelates of ethylenediaminetetraacetate in the dog. Toxic Appl Pharmac 18:10, 1971.
Ahrens FA and Aronson AL. Toxicity of calcium ethylenediaminetetraacetate in dogs. Fed Proc Fedn Am Soc Exp Biol 27:1401, 1968.
Adams WJ and McGee CT. Chelation therapy: a survey of treatment outcomes and selected socio-medical factors. J Adv Med 5(3):189, 1992.
Ahrens FA and Aronson AL. Comparative study of the toxic effects of calcium chelates of ethylene-diamine-tetraacetate in the dog. Tox Appl Pharmocol (18)1:10, 1971.
Aronov DM. First experience with the treatment of atherosclerosis patients with calcinosis of the arteries with trilon-B (disodium salt of EDTA). (Russ, Mosc) Klin Med 41:19, 1963.
Aronson AL and Ahrens FA. The mechanism of renal transport and excretion of ethylene-diamine-tetraacetate with interspecies comparison. Toxic Appl Pharm 18:1, 1971.
Bates GW, Billups C and Saltman P. The kinetics and mechanism of iron (III) exchange between chelates and transferrin. II. The presentation and removal with ethylenediaminetetraacetate. J Biol Chem 242:2816, 1967.
Bechtel JT, White JE and Estes EH Jr. The electrocardiographic effects of hypocalcemia induced in normal subjects with edathamil disodium. Circulation 13:837, 1956.
Bjorksten J. The cross-linkage theory of aging as a predictive indicator. Rejuvenation 8:59, 1980.
Bjorksten J. Possibilities and limitations of chelation as a means for life extension. Rejuvenation 8:67, 1980.
Blumer W and Cranton EM. Ninety percent reduction in cancer mortality after chelation therapy with EDTA. J Adv Med 2:183, 1989.
Boyle AJ, Clarke NE, Mosher RE, and McCann DS. Chelation therapy in circulatory and sclerosing diseases. Fed Proc 20(3) (Part II) (suppl 10):243-257, 1961.
Brucknerova O, Tulacek J, and Krojzl O. Chelates in the treatment of obliterating arteriopathies. Vnitrni Lek 14:841, 1968.
Brucknerova 0 and Malinovska V. First clinical experience with combined treatment with chelation III and glucagon in ischemic disease of the lower extremities, Cas Lek Cas 119:814, 1980.
Brucknerova 0 and Tulacek J. Chelates in the treatment of occlusive atherosclerosis. (Czech, Praha) Vnitr Lek 18:729, 1972.
BurckhardIt P, Boillat AM, Reudi B et al. Effect of parathyroid hormone immunoheterogeneity. Schweiz Med Wochenschr (105) 50:1692, 1975.
Butterfield JD and McGraw CP. Free radical pathology. Stroke 9(5):443, 1978.
Casdorph HR. EDTA chelation therapy: efficacy in arteriosclerotic heart disease. J Holist Med 3, 53-59, 1981.
Calcium disodium edetate and disodium edetate. Drugs for human use; drug efficacy study implementation. Department of Health, Education, and Welfare. FDA. Fed Reg 35 F.R. 437, 1970.
Casdorph HR. EDTA chelation therapy II: efficacy in brain disorders. J Holist Med 3(2):101-117, 1981.
Casdorph HR. Chelation therapy: a reappraisal. N Z Med J 66, 1983.
Casdorph HR and Farr CH. EDTA chelation therapy III: Treatment of peripheral arterial occlusion, an alternative to amputation. J Holist Med 3(1)5:3-15, 1983.
Casdorph HR. EDTA chelation therapy, efficacy in arteriosclerotic heart disease. J Holistic Medicine 3(1):53, 1981.
Chantler C and Barratt TM. Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child 47:613, 1972.
Chappell LT and Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 6(3):139, 1993.
Chappell LT, Stahl JP, and Evans R. EDTA chelation treatment for vascular disease: a meta-analysis using unpublished data. J Adv Med 7(3):131, 1994.
Chappell LT, Janson M, and Whitaker J. A challenge to cardiovascular surgeons. J Adv Med (In Press)
Chappell LT. EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Alt Ther Health Med 1:53, 1995.
Chen IW, Park HM, King LR, Bahr GK, and Goldsmith RE. Radioimmunoassay of parathyroid hormone: peripheral plasma immunoreactive parathyroid hormone response to ethylenediaminetetraacetate. J Nucl Med 15:763, 1974.
Cheraskin E, Wussow DG, McDonagh EW, and Rudolph CJ. Effect of EDTA chelation and supportive multivitamin/trace mineral supplementation with and without physical activity on the heart rate. J Intern Acad Prev Medi 8(6):5, 1984.
Clarke NE Sr, Clarke NE Jr, and Mosher RE. Treatment of occlusive vascular disease with disodium ethylene diamine tetraacetic acid (EDTA). Am J Med Sci :732, June 1960.
Clarke NE, Clarke CN, and Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetra-acetic acid. Am J Med Sci 232:654-666, 1956.
Clarke NE Sr. Atherosclerosis, occlusive vascular disease and EDTA. Am J Cardiol 6(2):233-236, 1960.
Clarke NE, Clarke CN, and Mosher RE. The "in vivo" dissolution of metastatic calcium: An approach to atherosclerosis. Am J Med Sci 229:142,1955.
Cohen SH, Gong JK and Fishler MC. Ethylene diamine tetraacetic acid (EDTA) treatment of internal radioactive contamination. Nucleonics (11)1: 56, 1953.
Cranton EM and Frackelton JP. The current status of EDTA chelation therapy in the treatment of occlusive arterial disease. J Holist Med 4: 24, 1982.
Cranton EM and Frackelton JP. Free radical pathology in age-associated disease: treatment with EDTA chelation, nutrition and anti-oxidants. J Holist Med 6 (1):6-37, 1984.
Cranton EM and Frackelton JP. Current status of EDTA chelation therapy in occlusive arterial disease. J Adv Med 2: 107-119, 1989.
Cranton EM. Protocol of the American College of Advancement in medicine for the safe and effective administration of EDTA chelation therapy. J Adv Med 2(1,2):269-306, 1989.
Deucher DP. EDTA chelation therapy: an antioxidant strategy. J Adv Med 1:182, 1988.
Deucher GP. Heayy metals, chelation therapy, free radicals and human disease. Angiol, Oct. 1987.
Fink CW and Baum J. Treatment of calcinosis universalis with chelating agents. Am J Dis Child 105:390, 1963.
Frackelton JP, Cranton EM. Iron and copper supplementation with EDTA chelation therapy. J Holist Med 8(1):63, 1986.
Frackelton JP. Monitoring renal function during EDTA chelation therapy. J Holist Med 8(1):33, 1986.
Fuleihan FJD, Kurban AK, Abboud RT, Beidas-jubran N, and Farah FS. An objective evaluation of the treatment of systemic scleroderma with disodium EDTA, pyridoxine and reserpine. Brit J Derm 80:184, 1968.
Godfrey ME, Agnihotri R, and Strauss A: Chelation and arteriosclerosis. N Z Med J 101(838):21, 1988.
Godfrey ME. EDTA chelation as a treatment of arteriosclerosis .N Z Med J 93:199, 1990.
Goodman and Gillman's pharmacological basis of therapeutics: heavy metals and heavy metal antagonists. 6:1615, 1980.
Gordon GB and Vance RB. EDTA chelation therapy for atherosclerosis: history and mechanisms of action. Osteopath Annals 4:38, 1976.
Gould RG. Metals and chelating agents in relation to atherosclerosis. Fed Proc 20 (Suppl 10):252, 1961.
Gutteridge JMC. Ferrous-salt-promoted damage to deoxyribose and benzoate. The increased effectiveness of hydroxyl-radical scavengers in the presence of EDTA. Biochem 243: 709-714, 1987.
Hancke C and Flytlie K. Benefits of EDTA chelation therapy in arteriosclerosis: a retrospective study of 470 patients. J Adv Med 6(3):161, 1993.
Hancke C. The long-term effect of chelation therapy: A 6- to 12-year follow up of a 1993 EDTA study. Clin Pract Alt Med spring 1(3):158-163, 2000.
Jick S and Karsh R. The effect of calcium chelation on cardiac arrhythmias and conduction disturbances. Am J Cardiol 4:287, 1959.
Johnson SAM. Use of the chelating agent edathamil disodium in acrosclerosis, sarcoidosis and other skin conditions with comments on tryptophan metabolism in sarcoidosis. Wiscons Med J 59:651, 1960.
Kay DS et al. The therapeutic effect of ascorbic acid and EDTA in manic-depressive psychosis: double-blind comparisons with standard treatments. Psychol Med 14(3):533-538, 1984.
Kaman RL, Rudolph CJ, Mcdonagh EW, and Walker FM. Effect of EDTA chelation therapy on aortic calcium in rabbits on atherogenic diets: quantitative and histochemical studies. J Adv Med 3(1):13, 1990.
Kindness G and Frackelton JP. Effect of ethylene diamine tetraacetic acid (EDTA) on platelet aggregation in human blood. J Adv Med 2(4):519, 1989.
Kitchell JR, Palmon F, Aytan N, and Meltzer LE. The treatment of coronary artery disease with disodium EDTA, a reappraisal. Am J Cardiol 11:501, 1963.
Lamb DJ and Leake DS. The effect of EDTA on the oxidation of low density lipoprotein. Atheroscl 94:35, 1992.
Lonsdale D. EDTA chelation therapy. Am J Surg 166:316, 1993.
Magee HR. Chelation treatment of atherosclerosis. Med J Aust 142:514, 1985.
Magee HR. Chelation therapy for atherosclerosis. Med J Aust 143:127, 1985.
Marcelle R and Lecomte J. On the cardiovascular activities of the sodium salt of ethylenediaminetetraacetic acid. C R Soc Biol 153:1483, 1959.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. Serum cholesterol and the aging process. Med Hypoth 7:685-694, 1981.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. The effect of EDTA salts plus supportive multi-vitamin/trace mineral supplementation upon renal function: A study of serum creatinine. J Holist Med 4:146-151, 1982.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. The effect of ethylene disodium ethylene diamine tetraacetic acid (EDTA) upon blood cholesterol in a private practice environment. J Int Acad Prev Med 7:5-12, 1982.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. An oculocerebrovasculometric analysis of the effect of EDTA chelation upon vascular stenosis. J Holist Med 4:21-23, 1982.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. The homeostatic effect of EDTA with supportive multivitamin trace mineral supplementation upon high-density lipoproteins (HDL). J Osteop Phys Surg Calif 8(2):34, Spring 1982.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. The effect of EDTA chelation therapy plus supportive multivitamin mineral supplementation upon renal function: A study in blood urea nitrogen (BUN). J Holist Med 4:21-23, 1982.
McDonagh EW, Rudolph CJ, and Cheraskin E. The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: A study in serum creatinine. J Holist Med 4:146, 1982.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. The influence of EDTA salts plus supportive vitamin mineral therapy upon total serum cholesterol/high-density lipoprotein cholesterol. Med Hypoth 9:643-646, 1982.
McDonagh EW, Rudolph CJ, and Cheraskin E. The glycohemoglobin (HbA1c) distribution in EDTA chelation eligible patients. J Orthomol Psych 12:72, 1983.
McDonagh EW, Rudolph CS, and Cheraskin E. The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: A study in blood urea nitrogen (BUN). J Holist Med 5(2):163, 1983.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. The effect of intravenenous disodium ethylene diamine tetraacetic acid (EDTA) plus supportive multivitamin/trace mineral supplementation upon fasting serum calcium. Med Hypoth 11:431-458, 1983.
Mc Donagh EW, Rudolph CJ, Cheraskin E, and Wussow DG. The effect of EDTA and supportive multivitamin/trace mineral supplementation with and without physical activity upon systolic blood pressure. J Orthomol Psych 13:1-9, 1984.
McDonagh EW, Rudolph CJ, and Cheraskin E. The effect of EDTA chelation therapy with multivitamin/trace mineral supplementation upon reported fatigue. J of Orthom Psych 13(4):1, 1984.
Mc Donagh EW, Rudolph CJ, and Cheraskin E. The effect of EDTA chelation therapy plus supportive multivitamin/trace mineral supplementation upon vascular dynamics (ankle/brachial systolic blood pressure). J Holist Med 7(1):16-22, 1985.
McDonagh EW, Rudolph CJ, and Cheraskin E. The clinical changes in patients treated with EDTA chelation plus multivitamin/trace mineral supplementation. The J Orthomol Psych 14(1):61, 1985.
McDonagh EW, Rudolph CJ, and Cheraskin E. The psychotherapeutic potential of EDTA chelation. The J Orthomol Psych 14(3):214, 1985.
Mc Donagh EW, Rudolph CJ, and Wussow DG. The effect of intravenous disodium ethylene diamine tetraacetic acid (EDTA) upon bone density levels. J Adv Med 1:79-85, 1988.
Mc Donagh EW, Rudolph CJ, and Barber RK. Effect of chelation and supportive multivitamin mineral supplementation on chronic lung disorders: A study of FVC and FEV1. J Adv Med 2:553-561, 1989.
Mc Donagh EW, Rudolph CJ, and Barber RK. An observation of the effect of EDTA chelation and supportive multivitamin mineral supplementation on blood platelet volume: A brief communication. J Adv Med 3(3):179-184, 1990.
McDonagh EW and Rudolph CJ. A collection of published papers showing the efficacy of EDTA chelation Therapy. Gladstone, MO, McDonagh Med Cent, 1991.
McGill WF. The effects of EDTA chelation therapy on plaque calcium and mineral metabolism in atherosclerotic rabbits. Dissert Abstr Int 41(4), Oct. 1980.
Naylor GJ and Smith AHW. Vanadium: a possible aetiological factor in manic-depressive illness. Psychol Med 11:249-256, 1981.
Nikitina EL and Abramova MA. Treatment of atherosclerosis patients with Trilon-B (EDTA). (Russ, Moscow) Kardiologiia 12:137, 1972.
Olszewer E and Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypoth 27: 41-49, 1988.
Olszewer E, Sabbag FC, and Carter JP. A pilot double blind study of sodium-magnesium EDTA in peripheral vascular disease. J Nat Med Assoc 82:173-177, 1988/1989.
Olszewer E and Carter JP. (EDTA) Chelation therapy: a retrospective study of 2,870 patients. J Adv Med 27: 197-211, 1989.
Peng CF, Kane JJ, Murphy ML, and Straub KD. Abnormal mitochondrial oxidative phosphorylation of ischemic myocardium reversed by calcium (Ca2) chelating agents. J Mol Cell Cardiol 9:897-908, 1977.
Riordan HD, Cheraskin E, Dirks M et al. Another look at renal function and the EDTA treatment proces. J Othom Med 2(3):185, 1987.
Riordon HD, Cheraskin E, Dirks M et al. Electrocardiographic changes associated with EDTA chelation therapy. J Adv Med 1:191, 1988.
Riordan HD, Cheraskin E, Dirks M et al. EDTA chelation/hypertension study: clinical patterns as judged by the Cornell Medical Index Questionnaire. J Orthom Med 4:91, 1989.
Rudolph CJ, McDonagh EW. The chelation carrier solution: An analysis of osmolarity and sodium content. J Int Acad Prev Med 8(1):26, 1983.
Rudolph CJ, McDonagh EW, and Wusson, DG. The effect of intravenous ethylene diamine tetraacetic acid (EDTA) upon bone density levels. J Adv Med 1(2):79, 1988.
Rudolph CJ, McDonagh EW, and Barber RK. Effect of EDTA chelation and supportive multivitamin/trace mineral supplementation on chronic lung disorders: a study of FVC and FEV1. J Adv Med 2(4):553, 1989.
Rudolph CJ, Mcdonagh EW, and Barber RK. An observation of the effect of EDTA chelation and supportive multivitamin/trace mineral supplementation on blood platelet volume: a brief communication. J Adv Med 3(3):179, 1990.
Rudolph CJ and McDonagh EW. Effect of EDTA chelation and supportive multivitamin trace mineral supplementation on carotid circulation: case report. J Adv Med 3(1):5, 1990.
Rudolph CJ, McDonagh EW, and Barber RK. A nonsurgical approach to obstructive carotid stenosis using EDTA chelation. J Adv Med, 4(3):157, 1991.
Rudolph CJ, McDonagh EW, and Barber RK. The effect of EDTA chelation on serum iron. J Adv Med 4:39, 1991.
Rudolph CJ, Samuels RT and McDonagh EW. Visual field evidence of macular degeneration reversal using a combination of EDTA and multiple vitamin and trace mineral therapy. J Adv Med 7:203, 1994.
Sehnert KW, Clague AF, and Cheraskin E. The improvement in renal function following EDTA chelation and multivitamin-trace mineral therapy: A study in creatinine clearance. Med Hypoth 15(3):307, 1984.
Simpson LO, Shand BI, and Olds RJ. Blood rheology and myalgic encephalomyelitis: a pilot study. Pathol 18(2):190-192, 1986.
Soffer A, Toribara T, Moore-Jones D, and Weber D: Clinical applications and untoward reactions and untoward reactions of chelation in cardiac arrhythmias. Arch Inten Med 106:824, 1960.
Soffer A and Toribara T. Changes in serum and spinal fluid calcium effected by disodium ethylenediaminetetraacetate. J Lab Clin Med (58):542, 1961.
Soffer A, Toribara T, and Sayman A: Myocardial responses to chelation. Brit Heart J 23:690, 1961.
Soffer A. Chelation therapy for arteriosclerosis. JAMA 233:1206, 1975.
Soffer A. Chihuahuas and laetrile, chelation therapy, and honey from Boulder, Colo. Arch Intern Med 136:865, 1976.
Soffer A. Chelation clinics, an abuse of the physician's freedom of choice. Chest 86:157, 1984.
Spencer H, Vankinscott V, Lewin I, and Lazlo D. Removal of calcium in man by ethylene diamine tetraacetic acid. (EDTA). J Clin Invest (31):1023, 1952.
Spencer H, Greenberg J, Berger E, Perrone M, and Lazlo D. Studies on the effect of ethylene-diamine-tetraacetic acid in hypercalcemia. J Lab Clin Med (47): 29, 1956.
Steinberg D, Parthasarathy S, Carew TE et al. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989.
Surawicz B, MacDonald M, Kaljot V et al. Treatment of cardiac arrythmias with salts of ethylene diamine tetraacetic acid (EDTA). Am Heart J (58):493, 1959.
Surawicz B. Use of chelating agent, ethylene diamine tetraacetic acid, in digitalis intoxication and cardiac arrhythrnias. Prog in Cardiovascular Dis p. 432, 1960.
Suvorov A and Markosyan RA. Some mechanisms of EDTA on platelet aggregation. (All Union Cardiol. Res. Cent. Moscow, Russia.) Byall Eksp Biol Med (1)5:587, 1981.
Van der Schaar P. Exercise tolerance tests in chelation therapy. J Adv Med 2(4): 563, 1989.
Van Rij AM, Solomon C, Packer SGK et al. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circul 90:1194, 1994.
Walker FMG. The effects of EDTA chelation therapy on plaque calcium and mineral metabolism in atherosclerotic rabbits. Physiology Vol. 41, No. 04, 1980.
Wartman A, Lampe TL, McCann DS, and Boyle AJ. Plaque reversal with Mg EDTA in experimental atherosclerosis: Elastin and collagen metabolism. J Athero Res 7:331, 1967.
Wilder LW, DeJode LR, Milstein SW et al. Mobilization of atherosclerotic plaque calcium with EDTA utilizing the isolation-perfusion principle. Surg 52:793, 1962.
Winder PR and Curtis AC. Edathamil in the treatment of scleroderma and calcinosis cutis. Arch Derm 82:732, 1960.
